Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1030522 | 1.00 | ACHE (0.46) | ACHEPAX8ESR2NR1H2GRM5 | |
| SCHEMBL12266171 | 0.93 | ACHE (0.44) | ACHEPAX8ESR2NR1H2GRM5 | |
| SCHEMBL2397980 | 0.93 | ACHE (0.44) | ACHEPAX8ESR2NR1H2GRM5 | |
| SCHEMBL25625337 | 0.88 | MAPK1 (0.50) | ACHEESR2NR1H2GRM5GRM1 | |
| SCHEMBL21343948 | 0.85 | GPR119 (0.48) | ACHEESR2NR1H2MAPK1 | |
| SCHEMBL4635083 | 0.81 | GRM5 (0.46) | ESR2NR1H2GRM5GRM1MEN1 | |
| SCHEMBL27773011 | 0.81 | ACHE (0.53) | ACHEPAX8HSD11B1MEN1KMT2A | |
| SCHEMBL5341385 | 0.80 | ESR2 (0.43) | ESR2NR1H2GRM5GRM1MEN1 | |
| SCHEMBL21369533 | 0.80 | ESR2 (0.43) | ESR2NR1H2GRM5GRM1MEN1 | |
| SCHEMBL5341383 | 0.80 | ESR2 (0.43) | ESR2NR1H2GRM5GRM1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1804791-B1 | TETRAHYDRO PYRIDINYL PYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-19 | — | — | EP | disclosed |
| EP-1804791-B1 | TETRAHYDRO PYRIDINYL PYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-19 | — | — | EP | disclosed |
| US-20060089378-A1 | Tetrahydro-pyridinyl pyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089378-A1 | Tetrahydro-pyridinyl pyrazole cannabinoid modulators | CNR2, CNR1, GPR18 | ACHE 1341/4885PAX8 4253/4885ESR2 1136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.